Skip to content

Study · Randomized controlled trial · 2022

4 results

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.

Yamada Y, Yabe D, Hertz CL, Horio H, Nakamura J, Nielsen AM, Seino Y

Diabetes, obesity & metabolism9 Nov 2021Cited by 18 (Europe PMC)

PMID34622548 (opens in a new tab)PMCIDPMC9299616 (opens in a new tab)DOI10.1111/dom.14571 (opens in a new tab)PepBankPUB-34622548
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, glycaemic efficacy of oral semaglutide was similar in patients younger than 65 years and those aged 65 years or older.

    In plain wordsIn Japanese adults with type 2 diabetes, oral semaglutide lowered blood sugar about equally in people under 65 and people 65 or older.

    Peptide
    Semaglutide
    Outcome
    No significant changeGlycaemic efficacy by baseline age
    Study

    n: not reported in source

    Comparator
    Patients aged <65 years versus 65 years or older
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3, 7 or 14 mg once daily · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Glycaemic efficacy of oral semaglutide was similar in Japanese patients aged <65 years compared with those ≥65 years
    1 context sentence
    Summary · context
    A post-hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (<65 and ≥65 years) on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese patients with type 2 diabetes, no clear pattern was seen between baseline age subgroup and body weight change with oral semaglutide.

    In plain wordsIn Japanese adults with type 2 diabetes, age did not show a clear pattern with weight change on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeBody weight change by baseline age
    Study

    n: not reported in source

    Comparator
    Patients aged <65 years versus 65 years or older
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3, 7 or 14 mg once daily · oral · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    there did not appear to be a clear pattern between age subgroup and body weight changes.
    1 context sentence
    Summary · context
    A post-hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (<65 and ≥65 years) on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 03HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    Across all treatment arms (oral semaglutide, liraglutide, dulaglutide, placebo), adverse events occurred in greater proportions of Japanese patients aged 65 years or older than of younger patients.

    In plain wordsAcross all treatment groups, older Japanese adults had adverse events more often than younger adults. This is not specific to semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseAdverse events by baseline age, across treatment arms
    Study

    n = 701

    Comparator
    Patients aged <65 years
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Across treatment arms, adverse events generally occurred in greater proportions of patients aged ≥65 versus <65 years.
    1 context sentence
    Summary · context
    A post-hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (<65 and ≥65 years) on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 04HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In Japanese patients with type 2 diabetes, premature trial product discontinuation because of adverse events was generally higher in the older age group; the sentence does not separate treatment arms.

    In plain wordsOlder Japanese adults in these trials generally stopped treatment early because of side effects more often than younger adults.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiscontinuation because of adverse events by baseline age
    Study

    n = 701

    Comparator
    Patients aged <65 years
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    There was generally a higher rate of premature trial product discontinuation because of adverse events in the older age group.
    1 context sentence
    Summary · context
    A post-hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (<65 and ≥65 years) on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 5 to 10Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 4

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 3

    12 Oct 2026, 11:11 UTC

    Study results updated

  4. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.